Johanna Mercier
At a glance: Johanna Mercier is Chief Comm & Corp Aff Officer at Gilead Sciences (GILD). Their latest SEC Form 4, filed Nov 17, 2026, reported a sale of $2.4M. On file: 0 purchase lines ($0) and 27 sale lines ($23.8M).
Disclosed holdings: about $18.5M of GILD stock: 110,684 shares reported on their latest Form 4 (filed Nov 17, 2026), valued at the Nov 19, 2026 close of $167.13. This counts only GILD shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Chief Comm & Corp Aff Officer at Gilead Sciences, Inc. (GILD); Chief Commercial Officer at Gilead Sciences, Inc. (GILD)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Johanna Mercier's InsiderPrint
27 trades from SEC Form 4 filings, 2025 to 2026, drawn as one fingerprint.
Reading this print: Almost only sells, trading about 25 times a year, typically $390K a trade; most sales are on a pre-planned 10b5-1 schedule.
- Bump outward: a purchase (0)
- Dent inward: a sale (27)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- James PursleyPresident · HNGE · 100% match
- Robert FauberCEO, President · MCO · 100% match
- Timothy HolmeCTO · QS · 100% match
- Stefan J. MurryCFO · AAOI · 100% match
- Colette KressCFO · NVDA · 100% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Nov 17SEC | GILDGilead Sciences, Inc. | Sell Plan | 13,922124,762 held (−10%) | $169.97 | $2.4M | -1.7% |
| Nov 17SEC | GILDGilead Sciences, Inc. | Sell Plan | 13,178111,584 held (−11%) | $171.09 | $2.3M | -2.3% |
| Nov 17SEC | GILDGilead Sciences, Inc. | Sell Plan | 900110,684 held (−1%) | $171.69 | $155K | -2.7% |
| Oct 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,000113,684 held (−3%) | $156.22 | $469K | +7.0% |
| Sep 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 1,600118,084 held (−1%) | $143.69 | $230K | +16.3% |
| Sep 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 800117,284 held (−1%) | $144.46 | $116K | +15.7% |
| Sep 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 600116,684 held (−1%) | $145.29 | $87K | +15.0% |
| Aug 18SEC | GILDGilead Sciences, Inc. | Sell Plan | 16,530129,704 held (−11%) | $137.37 | $2.3M | +21.7% |
| Aug 18SEC | GILDGilead Sciences, Inc. | Sell Plan | 11,470118,234 held (−9%) | $138.04 | $1.6M | +21.1% |
| Jul 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,000121,234 held (−2%) | $129.92 | $390K | +28.6% |
| Jun 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 1,480125,754 held (−1%) | $123.42 | $183K | +35.4% |
| Jun 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 1,070124,684 held (−1%) | $124.00 | $133K | +34.8% |
| Jun 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 450124,234 held (−0%) | $125.40 | $56K | +33.3% |
| May 18SEC | GILDGilead Sciences, Inc. | Sell Plan | 7,749146,030 held (−5%) | $130.29 | $1.0M | +28.3% |
| May 18SEC | GILDGilead Sciences, Inc. | Sell Plan | 11,177134,853 held (−8%) | $131.19 | $1.5M | +27.4% |
| May 18SEC | GILDGilead Sciences, Inc. | Sell Plan | 8,374126,479 held (−6%) | $132.23 | $1.1M | +26.4% |
| May 18SEC | GILDGilead Sciences, Inc. | Sell Plan | 700125,779 held (−1%) | $132.75 | $93K | +25.9% |
| Apr 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,000128,779 held (−2%) | $140.96 | $423K | +18.6% |
| Mar 17SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,000131,779 held (−2%) | $144.23 | $433K | +15.9% |
| Feb 18SEC | GILDGilead Sciences, Inc. | Sell Plan | 18,405129,883 held (−12%) | $154.18 | $2.8M | +8.4% |
| Feb 18SEC | GILDGilead Sciences, Inc. | Sell Plan | 9,395120,488 held (−7%) | $154.91 | $1.5M | +7.9% |
| Feb 18SEC | GILDGilead Sciences, Inc. | Sell Plan | 200120,288 held (−0%) | $155.62 | $31K | +7.4% |
| Jan 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,000103,221 held (−3%) | $124.31 | $373K | +34.5% |
| Dec 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,000106,221 held (−3%) | $122.00 | $366K | +37.0% |
| Nov 18SEC | GILDGilead Sciences, Inc. | Sell Plan | 25,524109,669 held (−19%) | $125.83 | $3.2M | +32.8% |
| Nov 18SEC | GILDGilead Sciences, Inc. | Sell Plan | 2,476107,193 held (−2%) | $126.26 | $313K | +32.4% |
| Oct 16SEC | GILDGilead Sciences, Inc. | Sell Plan | 3,000110,193 held (−3%) | $118.08 | $354K | +41.5% |
- Sell
Chief Comm & Corp Aff Officer Johanna Mercier sold $2.4M of GILD at $169.97 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Comm & Corp Aff Officer Johanna Mercier sold $2.3M of GILD at $171.09 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Comm & Corp Aff Officer Johanna Mercier sold $155K of GILD at $171.69 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Comm & Corp Aff Officer Johanna Mercier sold $469K of GILD at $156.22 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Comm & Corp Aff Officer Johanna Mercier sold $230K of GILD at $143.69 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Comm & Corp Aff Officer Johanna Mercier sold $116K of GILD at $144.46 — pre-scheduled 10b5-1 plan sale.
Follow Johanna Mercier
Get one email when Johanna Mercier files a new purchase or sale. Free.
At most one email a day about Johanna Mercier, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.